ArticleCancer letters2024

Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.

Florencia P Madorsky Rowdo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.